SecBot SecBot
DEFA14A ·Filed Jun 4, 2026

PCRX

Pacira BioSciences, Inc.
MIXED
Impact 6/10
Horizondays Processed5mo ago SEC0001628280-26-040814
Proxy solicitation materials
Actionable Insight ◆ Mixed

The proxy fight outcome is binary and will be resolved at the June 9 meeting. With all three major proxy advisors backing management, the incumbent slate is heavily favored. A DOMA win would introduce significant uncertainty around capital allocation and strategic direction. Monitor vote results post-meeting for potential board composition changes.

DirectionMixed
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$22.75
T+0 close · Jun 4, 2026 · via day close
Latest settled
+13.85%
T+60 · $25.90
Vs SPY
+9.85%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 5 $22.75entry
  2. T+1 · 5mo ago +0.48%α +0.26% · $22.86
  3. T+5 · 5mo ago +1.05%α +0.49% · $22.99
  4. T+20 · 4mo ago +12.48%α +10.62% · $25.59
  5. T+60 · 3mo ago +13.85%α +9.85% · $25.90
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Pacira BioSciences issued a DEFA14A press release reminding stockholders to vote FOR management's three director nominees (Christopher Christie, Samit Hirawat, MD, Thomas Wiggans) on the BLUE proxy card at the June 9, 2026 annual meeting, and AGAINST all three nominees from activist investor DOMA Perpetual Capital Management. The filing highlights record 2025 financial results, Q1 2026 revenue growth across all commercial products (EXPAREL +5%, ZILRETTA +15%, iovera +21% YoY), and endorsements from all three leading proxy advisory firms (ISS, Glass Lewis, Egan-Jones) supporting management's slate.

Key Financial Metrics

Vote
director election
Meeting
2026-06-09
Seats Contested
3

Key Facts

  • Annual meeting scheduled for June 9, 2026
  • Management nominees: Christopher Christie, Samit Hirawat, MD, Thomas Wiggans
  • Activist DOMA Perpetual Capital Management nominated three director candidates
  • All three proxy advisory firms (ISS, Glass Lewis, Egan-Jones) recommend FOR management's nominees
  • Q1 2026 EXPAREL revenue $143.3M (+5% YoY), ZILRETTA $26.8M (+15%), iovera $6.2M (+21%)
  • 2025 record total revenue $726.4M, GAAP gross margin 79.4%, non-GAAP gross margin 81.2%
  • Goldman Sachs acting as financial advisor, Perkins Coie as legal counsel
  • Key pipeline catalysts expected in 2026: Phase 2 PCRX-201 data in knee OA, registrational studies for ZILRETTA (shoulder OA) and iovera (spasticity)

Financial Impact

Record 2025 revenue of $726.4M with 79.4% GAAP gross margin; Q1 2026 product revenue growth of 5-21% YoY across portfolio

revenuegross margin

Risk Factors

  • Activist DOMA could win board seats despite proxy advisor opposition, potentially disrupting strategy
  • Pipeline readouts (PCRX-201 Phase 2, registrational studies) carry binary clinical risk
  • Revenue growth is modest (5-21% across products) and may not satisfy activist demands for faster value creation

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
69% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001628280-26-040814
Document: 0001628280-26-040814-index-headers.html0001628280-26-040814
Document: 0001628280-26-040814-index.html0001628280-26-040814
Document: 0001628280-26-040814.txt0001628280-26-040814

Track record

29 reports on PCRX

Performance horizon

5 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +42.26% at T+60 after the Aug 6, 2026 report. 8 of 9 went positive at some point.

Filters
  1. Nov 12, 20264d ago 8-K Bearish 6/10 Entry $36.46 Now $36.48 −0.05% settles Dec 14
  2. Nov 12, 20264d ago SC TO-T/A Mixed 7/10 Entry $36.46 Now $36.48 +0.05% settles Dec 14
  3. Nov 12, 20264d ago SC 14D-9/A Neutral 3/10 Entry $36.46 Now $36.48 +0.05% settles Dec 14
  4. Nov 5, 202611d ago 8-K Neutral 5/10 Entry $36.43 Now $36.48 +0.14% settles Dec 7
  5. Nov 3, 202613d ago SC 14D-9/A Neutral 3/10 Entry $36.40 Now $36.48 +0.22% settles Dec 3
  6. Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
  7. Oct 30, 202617d ago SC 14D-9 Bullish 7/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
  8. Oct 30, 202617d ago SC TO-T Mixed 7/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
  9. Oct 13, 20264w ago SC 13D/A Bearish 7/10 Entry $36.40 to $36.46 Now $36.48 −0.22% ▼ −0.16% −1.44% vs SPY
  10. Oct 8, 20265w ago SC TO-C Bullish 7/10 Entry $36.31 to $36.43 Now $36.48 +0.47% ▲ +0.33% +5.89% vs SPY
Showing 10 of 29

US Market Status

Market Closed · Opens in 7h 3m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 5, 2026